Fractyl Health reported one-year results from the REMAIN-1 study’s Midpoint Cohort: a single treatment with its Revita DMR System helped patients maintain more of their GLP-1-induced weight loss versus a sham procedure. The company characterized the outcome as better durability of weight-loss preservation over one year, supporting the investigational system’s effectiveness signal.
Fractyl Health reported one-year results from the REMAIN-1 study’s Midpoint Cohort: a single treatment with its Revita DMR System helped patients maintain more of their GLP-1-induced weight loss versus a sham procedure. The company characterized the outcome as better durability of weight-loss preservation over one year, supporting the investigational system’s effectiveness signal.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
